What is the share price of Dr Reddy's Laboratories Ltd (DRREDDY) today?
The share price of DRREDDY as on 25th July 2025 is ₹1278. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Dr Reddy's Laboratories Ltd (DRREDDY) share?
The past returns of Dr Reddy's Laboratories Ltd (DRREDDY) share are- Past 1 week: -0.98%
- Past 1 month: -5.54%
- Past 3 months: 5.41%
- Past 6 months: 3.36%
- Past 1 year: -7.22%
- Past 3 years: 44.68%
- Past 5 years: 55.62%
What are the peers or stocks similar to Dr Reddy's Laboratories Ltd (DRREDDY)?
The peers or stocks similar to Dr Reddy's Laboratories Ltd (DRREDDY) include:What is the dividend yield % of Dr Reddy's Laboratories Ltd (DRREDDY) share?
The current dividend yield of Dr Reddy's Laboratories Ltd (DRREDDY) is 0.63.What is the market cap of Dr Reddy's Laboratories Ltd (DRREDDY) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Dr Reddy's Laboratories Ltd (DRREDDY) is ₹105336.53 Cr as of 25th July 2025.What is the 52 week high and low of Dr Reddy's Laboratories Ltd (DRREDDY) share?
The 52-week high of Dr Reddy's Laboratories Ltd (DRREDDY) is ₹1421.49 and the 52-week low is ₹1020.What is the PE and PB ratio of Dr Reddy's Laboratories Ltd (DRREDDY) stock?
The P/E (price-to-earnings) ratio of Dr Reddy's Laboratories Ltd (DRREDDY) is 18.63. The P/B (price-to-book) ratio is 3.10.Which sector does Dr Reddy's Laboratories Ltd (DRREDDY) belong to?
Dr Reddy's Laboratories Ltd (DRREDDY) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Dr Reddy's Laboratories Ltd (DRREDDY) shares?
You can directly buy Dr Reddy's Laboratories Ltd (DRREDDY) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Dr Reddy's Laboratories Ltd
DRREDDY Share Price
DRREDDY Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
DRREDDY Performance & Key Metrics
DRREDDY Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
18.54 | 3.10 | 0.63% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
37.89 | 6.28 | 0.77% |
from 31 analysts
Price Upside
Earnings Growth
Rev. Growth
DRREDDY Company Profile
Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines.
DRREDDY Sentiment Analysis
DRREDDY Sentiment Analysis
DRREDDY Stock Summary · January 2025
In Q3FY25, the company showcased robust revenue growth, largely fueled by the acquisition of the Nicotine Replacement Therapy business, despite facing challenges such as price erosion in the North American generics market and integration costs impacting profitability. While the European generics segment thrived, emerging markets, particularly India, demonstrated solid year-over-year growth, underscoring the company's commitment to innovation and strategic investments in R&D and new product launches. The proactive approach to biosimilars, alongside a focus on sustainability and operational excellence, positions the company favorably for future opportunities. However, regulatory hurdles and competitive pressures necessitate careful navigation to sustain momentum and profitability across diverse markets. Overall, a cautious optimism prevails as the company aligns its growth strategies with evolving market dynamics.
DRREDDY Stock Growth Drivers
DRREDDY Stock Growth Drivers
7Strong Financial Performance
In Q3FY25, the company achieved consolidated revenues of Rs. 8,359 crores ($977 million), reflecting a
Successful Integration of Acquisitions
The company successfully consolidated the financials of the acquired NRT business in Q3FY25, contributing to
DRREDDY Stock Challenges
DRREDDY Stock Challenges
5Decline in Financial Performance
The company reported a decline in net finance income, dropping from Rs. 96 crores in
Slower Growth in Key Product Areas
Certain brands within the Cardiac and Gastro-intestinal therapy areas experienced slower growth, with overall growth
DRREDDY Forecast
DRREDDY Forecasts
Price
Revenue
Earnings
DRREDDY Share Price Forecast
DRREDDY Share Price Forecast
All values in ₹
All values in ₹
DRREDDY Company Revenue Forecast
DRREDDY Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
DRREDDY Stock EPS (Earnings Per Share) Forecast
DRREDDY Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
DRREDDY
DRREDDY
Income
Balance Sheet
Cash Flow
DRREDDY Income Statement
DRREDDY Income Statement
Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 14,367.60 | 14,436.20 | 15,829.50 | 18,193.70 | 19,386.90 | 22,099.90 | 25,762.20 | 28,920.10 | 33,762.90 | 34,806.00 | ||||||||||
Raw Materials | 3,819.80 | 4,081.00 | 4,770.20 | 5,530.70 | 6,869.40 | 7,796.10 | 7,586.80 | 8,889.20 | 10,524.60 | 24,998.90 | ||||||||||
Power & Fuel Cost | 330.10 | 329.30 | 329.10 | 314.80 | 320.50 | 390.50 | 477.40 | 533.90 | 562.50 | |||||||||||
Employee Cost | 3,106.80 | 3,214.90 | 3,356.20 | 3,380.20 | 3,629.90 | 3,885.80 | 4,646.60 | 5,030.10 | 5,580.00 | |||||||||||
Selling & Administrative Expenses | 3,287.10 | 2,106.10 | 2,235.30 | 2,184.20 | 2,398.30 | 2,976.10 | 3,199.30 | 3,710.20 | 4,736.30 | |||||||||||
Operating & Other expenses | 1,180.10 | 2,198.50 | 1,579.20 | 3,636.70 | 1,959.50 | 2,729.00 | 2,410.60 | 1,914.60 | 2,693.40 | |||||||||||
EBITDA | 2,643.70 | 2,506.40 | 3,559.50 | 3,147.10 | 4,209.30 | 4,322.40 | 7,441.50 | 8,842.10 | 9,666.10 | 9,807.10 | ||||||||||
Depreciation/Amortization | 1,026.60 | 1,077.20 | 1,134.80 | 1,163.10 | 1,228.80 | 1,165.20 | 1,250.20 | 1,470.00 | 1,703.70 | 1,799.20 | ||||||||||
PBIT | 1,617.10 | 1,429.20 | 2,424.70 | 1,984.00 | 2,980.50 | 3,157.20 | 6,191.30 | 7,372.10 | 7,962.40 | 8,007.90 | ||||||||||
Interest & Other Items | 63.40 | 78.80 | 88.90 | 98.30 | 97.00 | 95.80 | 142.80 | 171.10 | 282.90 | 306.00 | ||||||||||
PBT | 1,553.70 | 1,350.40 | 2,335.80 | 1,885.70 | 2,883.50 | 3,061.40 | 6,048.50 | 7,201.00 | 7,679.50 | 7,701.90 | ||||||||||
Taxes & Other Items | 261.60 | 403.60 | 385.80 | -140.30 | 931.90 | 878.90 | 1,541.20 | 1,623.10 | 2,024.40 | 2,021.10 | ||||||||||
Net Income | 1,292.10 | 946.80 | 1,950.00 | 2,026.00 | 1,951.60 | 2,182.50 | 4,507.30 | 5,577.90 | 5,655.10 | 5,680.80 | ||||||||||
EPS | 15.37 | 11.42 | 23.50 | 24.39 | 23.48 | 26.24 | 54.15 | 66.93 | 67.78 | 68.08 | ||||||||||
DPS | 4.00 | 4.00 | 4.00 | 5.00 | 5.00 | 6.00 | 8.00 | 8.00 | 8.00 | 8.00 | ||||||||||
Payout ratio | 0.26 | 0.35 | 0.17 | 0.20 | 0.21 | 0.23 | 0.15 | 0.12 | 0.12 | 0.12 |
DRREDDY Company Updates
Investor Presentation
DRREDDY Stock Peers
DRREDDY Past Performance & Peer Comparison
DRREDDY Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Dr Reddy's Laboratories Ltd | 18.63 | 3.10 | 0.63% |
Sun Pharmaceutical Industries Ltd | 37.15 | 5.60 | 0.95% |
Cipla Ltd | 22.80 | 3.84 | 1.08% |
Torrent Pharmaceuticals Ltd | 62.33 | 15.69 | 0.91% |
DRREDDY Stock Price Comparison
Compare DRREDDY with any stock or ETFDRREDDY Holdings
DRREDDY Shareholdings
DRREDDY Promoter Holdings Trend
DRREDDY Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
DRREDDY Institutional Holdings Trend
DRREDDY Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
DRREDDY Shareholding Pattern
DRREDDY Shareholding Pattern
DRREDDY Shareholding History
DRREDDY Shareholding History
Mutual Funds Invested in DRREDDY
Mutual Funds Invested in DRREDDY
No mutual funds holding trends are available
Top 5 Mutual Funds holding Dr Reddy's Laboratories Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.1854% | Percentage of the fund’s portfolio invested in the stock 1.20% | Change in the portfolio weight of the stock over the last 3 months -0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 20/177 (-3) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.1358% | Percentage of the fund’s portfolio invested in the stock 2.21% | Change in the portfolio weight of the stock over the last 3 months 0.55% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 51/91 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.6100% | Percentage of the fund’s portfolio invested in the stock 1.47% | Change in the portfolio weight of the stock over the last 3 months -0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 21/77 (-1) |
Compare 3-month MF holding change on Screener
smallcases containing DRREDDY stock
smallcases containing DRREDDY stock
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Dr Reddy's Laboratories Ltd
DRREDDY Events
DRREDDY Events
DRREDDY Dividend Trend
DRREDDY has increased or maintained dividend levels over the last 5 years
Current dividend yield is 0.63%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹6.34 every year
Dividends
Corp. Actions
Announcements
Legal Orders
DRREDDY Dividend Trend
DRREDDY has increased or maintained dividend levels over the last 5 years
Current dividend yield is 0.63%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹6.34 every year
DRREDDY Upcoming Dividends
DRREDDY Upcoming Dividends
No upcoming dividends are available
DRREDDY Past Dividends
DRREDDY Past Dividends
Cash Dividend
Ex DateEx DateJul 10, 2025
Dividend/Share
₹8.00
Ex DateEx Date
Jul 10, 2025
Cash Dividend
Ex DateEx DateJul 16, 2024
Dividend/Share
₹40.00
Ex DateEx Date
Jul 16, 2024
Cash Dividend
Ex DateEx DateJul 11, 2023
Dividend/Share
₹40.00
Ex DateEx Date
Jul 11, 2023
Cash Dividend
Ex DateEx DateJul 11, 2022
Dividend/Share
₹30.00
Ex DateEx Date
Jul 11, 2022
Cash Dividend
Ex DateEx DateJul 9, 2021
Dividend/Share
₹25.00
Ex DateEx Date
Jul 9, 2021
DRREDDY Stock News & Opinions
DRREDDY Stock News & Opinions
Profit before tax (PBT) stood at Rs 1,905 crore in Q1 FY26, up 1.2% YoY EBITDA for the quarter stood at Rs 2,278.4 crore, up 5.49% YoY. In its global generics business, North America contributed Rs 3,412.3 crore in revenue, a 11% year-on-year decline. Revenue from Europe surged 142% to Rs 1,274.4 crore, The India business generated revenue of Rs 1,471.1 crore, registering an 11% YoY. Revenue from Pharmaceutical Services and Active Ingredients (PSAI) came in at Rs 818.1 crore, a 7% YoY increase. Co-Chairman & MD, G V Prasad, said: We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio. The pricing pressure on Lenalidomide is expected to intensify in the U.S. generics market. We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development. Hyderabad-based Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.Powered by Capital Market - Live
In a regulatory filing, the company stated that the EIR was issued following a good manufacturing practice (GMP) inspection conducted by the USFDA. The inspection outcome has been classified as Voluntary Action Indicated (VAI), and the inspection is now officially closed under 21 CFR 20.64(d)(3). This follows Dr. Reddy's earlier disclosure dated 17 May 2025, in which it informed that the USFDA had completed a GMP inspection of the Middleburgh facility. The inspection took place from 12 May to 16 May 2025 (US EST) and concluded with the issuance of a Form 483 containing two observations. The company confirmed that it will address the observations within the stipulated timeline. Hyderabad-based Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Dr. Reddy's Laboratories reported a consolidated net profit of Rs 1,594 crore for the quarter ended March 2025 (Q4FY25), marking a 22% year-on-year increase from Rs 1,307 crore in the same period last year. Revenue from operations rose 20% year-on-year to Rs 8,506 crore, compared to Rs 7,083 crore in Q4FY24. The scrip shed 0.44% to Rs 1,254 on the BSE. Powered by Capital Market - Live
Dr Reddys Laboratories Ltd is down for a fifth straight session today. The stock is quoting at Rs 1267.7, down 0.71% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.38% on the day, quoting at 25444.25. The Sensex is at 83364.59, down 0.4%.Dr Reddys Laboratories Ltd has added around 1.55% in last one month.Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has increased around 3.31% in last one month and is currently quoting at 22041.25, up 0.09% on the day. The volume in the stock stood at 13.42 lakh shares today, compared to the daily average of 16.98 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 1267.5, down 0.76% on the day. Dr Reddys Laboratories Ltd tumbled 1.36% in last one year as compared to a 4.77% rally in NIFTY and a 10.78% spurt in the Nifty Pharma index.The PE of the stock is 19.92 based on TTM earnings ending March 25.Powered by Capital Market - Live
Dr Reddys Laboratories will hold a meeting of the Board of Directors of the Company on 23 July 2025.Powered by Capital Market - Live
Dr Reddys Laboratories has allotted 10,685 equity shares under ESOPs on 23 June 2025. Powered by Capital Market - Live
Dr Reddys Laboratories has allotted 57,885 equity shares of Re.1/- each of the Company, fully paid up, on June 14, 2025, to eligible employees pursuant to exercise of their Stock Options under Dr. Reddy's Employees Stock Options Scheme, 2002 and Dr. Reddy's Employees ADR Stock Options Scheme, 2007.Powered by Capital Market - Live
Dr Reddys Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 1364.9, up 1.02% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.28% on the day, quoting at 25069.95. The Sensex is at 82276.06, down 0.29%. Dr Reddys Laboratories Ltd has gained around 13.07% in last one month. Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has gained around 4.05% in last one month and is currently quoting at 22057.15, up 0.76% on the day. The volume in the stock stood at 11.71 lakh shares today, compared to the daily average of 17.74 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1361.1, up 0.71% on the day. Dr Reddys Laboratories Ltd is up 11.95% in last one year as compared to a 7.14% jump in NIFTY and a 12.03% jump in the Nifty Pharma index.The PE of the stock is 21.07 based on TTM earnings ending March 25.Powered by Capital Market - Live
Dr Reddys Laboratories Ltd gained for a fifth straight session today. The stock is quoting at Rs 1321.8, up 0.07% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.46% on the day, quoting at 25117.25. The Sensex is at 82511.15, up 0.39%. Dr Reddys Laboratories Ltd has risen around 10.56% in last one month. Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has risen around 3.24% in last one month and is currently quoting at 21684.4, up 0.47% on the day. The volume in the stock stood at 9.1 lakh shares today, compared to the daily average of 19.37 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1320.2, up 0.24% on the day. Dr Reddys Laboratories Ltd is up 8.24% in last one year as compared to a 7.99% spurt in NIFTY and a 10.18% spurt in the Nifty Pharma index.The PE of the stock is 20.6 based on TTM earnings ending March 25.Powered by Capital Market - Live
Keytruda, a widely used immunotherapy for various cancer types, recorded global sales of $29.5 billion in 2024. The partnership involves joint development and manufacturing of the biosimilar, with both companies sharing costs and responsibilities. Subject to certain conditions, both parties will also have rights to commercialize the product worldwide. Alvotech, a biotech company focused on biosimilars, already has two approved biosimilars, adalimumab and ustekinumab, marketed in several countries. It has a strong pipeline of nine additional biosimilars and a global network of commercial partnerships spanning the US, Europe, Asia, Latin America, and Africa. Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. On a consolidated basis, net profit of Dr Reddy's Laboratories rose 21.64% to Rs 1593.30 crore while net sales rose 20.09% to Rs 8506 crore in Q4 March 2025 over Q4 March 2024. Powered by Capital Market - Live
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (Alvotech), and Dr. Reddy's Laboratories announced that the companies have entered into a collaboration and license agreement to co develop, manufacture and commercialize a biosimilar candidate to Keytruda' (pembrolizumab) for global markets. Keytruda' (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales of Keytruda were US$29.5 billion [1]. The collaboration combines Dr. Reddy's and Alvotech's proven capabilities in biosimilars, thereby, speeding up the development process and extending the global reach for this biosimilar candidate. Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. Subject to certain exceptions, each party will have the right to commercialize the product globally.Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 13.16%, vs industry avg of 10.15%
Over the last 5 years, market share increased from 7.25% to 8.06%
Over the last 5 years, net income has grown at a yearly rate of 22.79%, vs industry avg of 20.04%